CD8A and sarcoma: We previously identified the unique major MHC-I and MHC-II neoAgs expressed in three of our methylcholanthrene (MCA) sarcoma lines (Supplementary Table 1), showed that immune rejection of each tumour depends on CD4+ and CD8+ T cell responses to the neoAgs uniquely expressed in each tumour line, and further showed that optimal rejection efficacy required the presence of both MHC-I and MHC-II neoAgs in tumours and vaccines8,19,20.